2024-12-16T10:33:29-06:00 2024-03-31 541342298 Kositzka Wicks and Company 5270 Shawnee Road Suite 250 Alexandria VA 22312 990 2023-04-01 202510044 The Side-Out Foundation SIDE 8773447465 11208 Waples Mill Road 103 Fairfax VA 22030 Rick Dunetz Executive Director 8773447465 2024-12-11 1 1 Jennifer S Manster CPA P01383338 7036422700 2023 2024-10-15 13:58:12Z Rick Dunetz 11208 Waples Mill Road 103 Fairfax VA 22030 1383172 0 X www.side-out.org X 2005 VA Making breast cancer a manageable disease (similar to diabetes) takes an organization with extraordinary vision & cutting-edge tactics. The Side-Out Foundation is a 501(c)(3) non-profit organization, founded in 2004 by Richard and Bryant Dunetz, to empower a new generation of advocates, make significant and identifiable impact on the way breast cancer is treated, and give those living with metastatic breast cancer (MBC) more tomorrows.Since its inception, the foundation has (I) built educational and community-driven programs focused on teaching advocacy to the next generation of changemakers, equipping them with skills and tools to support Side-Out's mission, as well as any cause they wish to connect to in their future; (II) forged groundbreaking collaborations with prestigious research teams, hospitals, and research centers nationwide and; (III) leveraged new technologies to improve, alter cancer trajectories, and constantly challenge the foundation of cancer care. 3 2 9 0 0 0 1230616 1306378 0 0 802 46980 1091 8111 1232509 1361469 29223 4345 0 0 613445 549462 0 0 79312 706877 635190 1349545 1188997 -117036 172472 2116765 2115644 420164 246571 1696601 1869073 X See Schedule O. 0 0 857363 4345 Our foundation funded two significant research projects stemming from the Side Out 3 clinical trial, focusing on identifying molecular biomarkers that indicate non-response to first-line endocrine treatment with Cdk4/6 inhibitors (like Ibrance) in ER+/HER2- metastatic breast cancer (MBC) patients. Through our funded laboratory research, we are developing an innovative therapeutic approach for patients likely to progress beyond standard care. The promising preclinical data continues to validate clinical observations, positioning us to establish a groundbreaking clinical trial offering novel therapeutic options to MBC patients who don't benefit from standard care. To our knowledge, this therapeutic approach would be the first of its kind for MBC patients.Additionally, through our patient-centered precision medicine initiative contracted to Perthera, we conducted an interim analysis using real-world data from enrolled patients. This research demonstrated the effectiveness of a multi-omic approach in predicting drug target activation and treatment response in individual patients. Our funded research, published in the "British Journal of Cancer," showed that combining genomic, proteomic, and phosphoproteomic data may better identify patients suitable for the newly FDA-approved second-line treatment, capivasertib, compared to using genomic data alone. This year's comprehensive research efforts have significantly advanced the understanding of MBC biology, enhanced diagnostic approaches available to physicians for tailoring MBC patient treatments, and initiated preclinical testing of promising new therapeutic options specifically for patients affected by ER+/HER2- MBCs. 857363 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 1 9 1 0 0 0 0 0 0 0 0 0 0 0 0 X 3 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 1 1 0 AL AR CA FL GA IL KS KY MD MA MI MN MS NH NJ NY NC OH OK PA RI SC UT VA WV WY X Rick Dunetz 7036158740 11208 Waple Mill Rd 103 Fairfax VA 22030 Rick Dunetz Chief Vision Officer 40.00 X X 85425 0 3714 Gary Thompson Board chair 1.00 X X 0 0 0 Stephanie Reffey Director 1.00 X 0 0 0 Ellen Dempsey Executive Director 40.00 X 75000 0 2557 160425 0 6271 0 0 0 0 0 1306378 1306378 46980 46980 29814 21703 8111 8111 1361469 8111 0 46980 X 4345 4345 220287 121158 93622 5507 278013 236311 27801 13901 7213 6131 721 361 3618 3075 362 181 40331 30248 8401 1682 565 565 34867 24407 10460 214991 171992 4565 38434 30618 6124 24494 9730 9730 6901 5521 1035 345 59661 47729 8949 2983 28432 25826 2606 7657 6891 766 4626 4626 Clinical trial 140102 140102 Recruiting and developm 35825 35825 Subscriptions 35255 28204 5288 1763 Payroll expenses 13038 9782 2713 543 12922 8733 3643 546 1188997 857363 252322 79312 1819564 1868528 18439 39268 3795 3795 10353 348 546790 539687 14224 7103 250390 196602 2116765 2115644 8516 29889 411648 216682 420164 246571 X 1696601 1869073 1696601 1869073 2116765 2115644 172472 0 X 0 1 X 0 0 X 1359341 400020 1127967 1230616 1306378 5424322 44471 7460 26778 13750 29814 122273 1403812 407480 1154745 1244366 1336192 5546595 0 0 0 5546595 1138 197 102 802 46980 49219 1138 197 102 802 46980 49219 1200 1200 1404950 408877 1154847 1245168 1383172 5597014 0.99100 0.99870 0.00880 0.00060 X Schedule A, Part III, Line 12, Explanation of Other Income: Cashback rebates - 2020 Amount: $ 1,200. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1875 552 1323 27465 22625 4840 517450 516510 940 7103 Security deposit 5928 Operating right-of-use asset 190674 196602 Operating lease liabilities 216682 216682 X 1386474 25005 25005 1361469 0 1361469 1214002 25005 25005 1188997 0 1188997 Part X, Line 2: On January 1, 2009, the Foundation adopted the provisions of FASB ASC Topic 740-10 Income Taxes. The implementation of FASB ASC Topic 740-10 had no impact on the Foundation's financial statements and, accordingly, no interest or penalties have been accrued. Management believes it has no material uncertain tax positions or any related penalties and interest to accrue for the year ended March 31, 2024, and accordingly, there is no liability for unrecognized benefits. Form 990, Part VI, Section B, line 11b The Executive Director and Secretary review the return. Form 990, Part VI, Section B, line 12c Written conflict of interest policy is in place and monitored at all levels of the organization. Form 990, Part VI, Section B, line 15 The Board reviews and approves compensation for all leadership positions. Form 990, Part VI, Section C, line 19 No other documents are available to the public. Form 990, Part IX, line 11g Website and software services: Program service expenses 24,345. Management and general expenses 4,565. Fundraising expenses 1,522. Total expenses 30,432. Consultants: Program service expenses 147,647. Management and general expenses 0. Fundraising expenses 36,912. Total expenses 184,559.